Association of tumor immune microenvironment profiling and 21-gene recurrence assay in early breast cancer patients

被引:3
|
作者
Tong, Yiwei [1 ]
Huang, Jiahui [1 ]
Ren, Weili [2 ]
Yu, Jing [1 ]
Zhang, Xu [1 ]
Wang, Zheng [1 ]
Hong, Jin [1 ]
Gao, Weiqi [1 ]
Wu, Jiayi [1 ]
Ji, Min [3 ]
Shen, Kunwei [1 ]
Chen, Xiaosong [1 ]
机构
[1] Shanghai Jiao Tong Univ, Ruijin Hosp, Comprehens Breast Hlth Ctr, Dept Gen Surg,Sch Med, 197 Ruijin Er Rd, Shanghai 200025, Peoples R China
[2] Shaoxing Shangyu Peoples Hosp, Dept Breast Surg, Shaoxing 312300, Zhejiang, Peoples R China
[3] Shanghai Jiao Tong Univ, Int Peace Matern & Child Hlth Hosp, Dept Breast, Sch Med, 910 Hengshan Rd, Shanghai 200030, Peoples R China
基金
中国国家自然科学基金;
关键词
Breast cancer; Tumor immune microenvironment; Immune profiling; 21-gene recurrence score; Prognosis; INTERNATIONAL EXPERT CONSENSUS; INFILTRATING LYMPHOCYTES; PRIMARY THERAPY; DUCTAL CARCINOMA; PROGNOSTIC VALUE; HIGHLIGHTS; ADJUVANT; PROPOSAL; TRIALS;
D O I
10.1186/s40001-022-00917-3
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Introduction: Tumor immune microenvironment (TIME) plays a vital role in breast cancer development, treatment resistance, and prognosis. This study evaluates the association of TIME profiling and 21-gene recurrence score (RS) in early Luminal breast cancer patients.Methods: ER+ /HER2-, pN0 breast cancer patients with available RS results who received surgery between January 2009 and December 2013 were enrolled. TIME markers, including stromal tumor infiltrating lymphocytes (TILs), CD3, CD4, CD8, and tumor PD-L1 expression, were comprehensively analyzed. Association of TIME markers with RS, as well as their correlation with breast cancer-specific survival (BCSS) were tested.Results: Overall, 385 patients were included, of whom 341 (88.6%) had TILs <= 10%. TIME markers were positively but moderately correlated with each other (Spearman r 0.28-0.53, all P < 0.05). Continuous RS showed a weak correlation with continuous TILs, CD3, CD8, and PD-L1. Regarding single gene mRNA level in the 21-gene RS panel, higher expression of TIME markers was related to lower ER group genes expression, but higher proliferation and invasion group genes level. After a median follow-up of 91.67 (range 5.03-134.03) months, TILs (P = 0.049) and PD-L1 (P = 0.034) were inversely associated with BCSS.Conclusions: Breast cancer TIME markers, including TILs, CD3, CD4, CD8, and PD-L1, were correlated with 21-gene RS score. Lower expression of ER group genes, as well as higher expression of proliferation and invasion group genes were associated with a higher level of these TIME markers, warranting further exploration.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Utilization and outcomes of the 21-gene recurrence score in de novo metastatic breast cancer
    Yang, Shi-Ping
    Liu, Ke
    Li, Yang
    Li, Guan-Qiao
    Li, Jia-Yi
    Lin, Yu-Yi
    Wu, San-Gang
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2024, 24 (1-2) : 99 - 106
  • [32] Impact of the 21-gene recurrence score on outcome in patients with invasive lobular carcinoma of the breast
    Kizy, Scott
    Huang, Jing Li
    Marmor, Schelomo
    Tuttle, Todd M.
    Hui, Jane Yuet Ching
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 165 (03) : 757 - 763
  • [33] Cost-Effectiveness of the 21-Gene Breast Cancer Assay in Mexico
    Juan Enrique Bargalló-Rocha
    Fernando Lara-Medina
    Victor Pérez-Sánchez
    Rafael Vázquez-Romo
    Cynthia Villarreal-Garza
    Hector Martínez-Said
    Robin J. Shaw-Dulin
    Alejandro Mohar-Betancourt
    Barnaby Hunt
    Juliette Plun-Favreau
    William J. Valentine
    Advances in Therapy, 2015, 32 : 239 - 253
  • [34] Economic impact of 21-gene recurrence score testing on early-stage breast cancer in Ireland
    Smyth, Lillian
    Watson, Geoff
    Walsh, Elaine M.
    Kelly, Catherine M.
    Keane, Maccon
    Kennedy, M. John
    Grogan, Liam
    Hennessy, Bryan T.
    O'Reilly, Seamus
    Coate, Linda E.
    O'Connor, Miriam
    Quinn, Cecily
    Verleger, Katharina
    Schoeman, Olaf
    O'Reilly, Susan
    Walshe, Janice M.
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 153 (03) : 573 - 582
  • [35] Surgeon and medical oncologist peer network effects on the uptake of the 21-gene breast cancer recurrence score assay
    Zipkin, Ronnie
    Schaefer, Andrew
    Chamberlin, Mary
    Onega, Tracy
    O'Malley, Alistair J.
    Moen, Erika L.
    CANCER MEDICINE, 2021, 10 (04): : 1253 - 1263
  • [36] Combined pathologic-genomic algorithm for early-stage breast cancer improves cost-effective use of the 21-gene recurrence score assay
    Gage, M. M.
    Mylander, W. C.
    Rosman, M.
    Fujii, T.
    Le Du, F.
    Raghavendra, A.
    Sinha, A. K.
    Fernandez, J. R. Espinosa
    James, A.
    Ueno, N. T.
    Tafra, L.
    Jackson, R. S.
    ANNALS OF ONCOLOGY, 2018, 29 (05) : 1280 - 1285
  • [37] 21-gene recurrence score and adjuvant chemotherapy decisions in patients with invasive lobular breast cancer
    Chen, Xiang-Hong
    Zhang, Wen-Wen
    Wang, Jun
    Sun, Jia-Yuan
    Li, Feng-Yan
    He, Zhen-Yu
    Wu, San-Gang
    BIOMARKERS IN MEDICINE, 2019, 13 (02) : 83 - 93
  • [38] Utilization and Outcomes of the 21-Gene Recurrence Score in pN2 Breast Cancer Patients
    Haque, Waqar
    Verma, Vivek
    Mangalampalli, Niva
    Schwartz, Mary r.
    Butler, E. brian
    Sun, Kai
    Jain, Dharamvir
    Arentz, Candy
    Ramakrishnan, Akshay
    Teh, Bin s.
    ANTICANCER RESEARCH, 2025, 45 (03) : 1055 - 1061
  • [39] Multigene testing in breast cancer: What have we learned from the 21-gene recurrence score assay?
    Turashvili, Gulisa
    Wen, Hannah Y.
    BREAST JOURNAL, 2020, 26 (06) : 1199 - 1207
  • [40] Economic impact of 21-gene recurrence score testing on early-stage breast cancer in Ireland
    Lillian Smyth
    Geoff Watson
    Elaine M. Walsh
    Catherine M. Kelly
    Maccon Keane
    M. John Kennedy
    Liam Grogan
    Bryan T. Hennessy
    Seamus O’Reilly
    Linda E. Coate
    Miriam O’Connor
    Cecily Quinn
    Katharina Verleger
    Olaf Schoeman
    Susan O’Reilly
    Janice M. Walshe
    Breast Cancer Research and Treatment, 2015, 153 : 573 - 582